Daniel W. Drolet
12Patents
4h-index
14Co-inventors
57Inventor score
Filing activity: Jun 17, 1999 → Feb 22, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6544776B1 | Nucleic acid ligand diagnostic biochip | Emerging Cross-Sectional Technologies | 46 | Expired |
| US10221421B2 | Post-selec modification methods | Chemistry; Metallurgy | 11 | Active |
| US6280943A | 2'-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands | Chemistry; Metallurgy | 9 | Expired |
| US6387635B1 | 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands | Chemistry; Metallurgy | 6 | Expired |
| US9695424B2 | PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders | Chemistry; Metallurgy | 3 | Active |
| US9410156B2 | Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions | Chemistry; Metallurgy | 3 | Active |
| US9701967B2 | Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions | Chemistry; Metallurgy | 3 | Active |
| US6673553B2 | 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands | Chemistry; Metallurgy | 3 | Expired |
| US9994857B2 | PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders | Chemistry; Metallurgy | 2 | Active |
| US10544419B2 | PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders | Chemistry; Metallurgy | 1 | Active |
| US11466275B2 | Nucleic acid compounds for binding to complement component 3 protein | Chemistry; Metallurgy | 0 | Active |
| US11208663B2 | Post-selex modification methods | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.